Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change


Related Publications

Smolina K, Weymann D, Morgan S, Ross C, Carleton B. Association between regulatory advisories and codeine prescribing to postpartum women. Journal of the American Medical Association. 2015;313(18):1861-2.
Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.

Publication Topics

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change

Publication TypeJournal Article
Year of Publication2008
AuthorsSoumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law M, Hughes TE, Chapman D, Adams AS
JournalHealth affairs (Project Hope)Health.Aff.(Millwood)
Pagesw185 - 95
Date Published2008
KeywordsAdolescent, Adult, Antipsychotic Agents/therapeutic use, Drug Utilization/statistics & numerical data, Female, Health Policy, Humans, Insurance Claim Review, Maine, Male, Medicaid, Medicare Part D, Middle Aged, New Hampshire, Proportional Hazards Models, Schizophrenia/drug therapy/economics, United States, Young Adult
AbstractMore than one-third of Medicaid programs and Medicare Part D plans use prior authorization (PA) policies to control the use of atypical antipsychotics (AAs). We used Medicaid and Medicare claims data to investigate how Maine's PA policy affected AA use, treatment discontinuities, and spending among schizophrenia patients initiating AA therapy. Patients initiating AAs during Maine's policy experienced a 29 percent greater risk of treatment discontinuity than patients initiating AAs before the policy took effect; no change occurred in a comparison state. AA spending was slightly lower in both states. Observed increases in treatment discontinuities without cost savings suggest that AAs should be exempt from PA for patients with severe mental illnesses.
Citation Key473